Latest European Markets News

CD Private Equity Fund I (ASX:CD1) posted a net loss of $6.96 million for the year ended 31 March 2026, driven by a $5.14 million fair value decline in its US private equity holdings and significant foreign exchange pressures. Despite near-term setbacks, the Fund has delivered an 8.3% post-tax annual return since inception.

Vista Group has landed a significant contract to transition Cineplexx’s European cinema circuit to its cloud-based Operational Excellence platform, covering 59 sites and over 400 screens across 11 countries.

Memphasys has rapidly established a foothold in the UK IVF market, securing four active commercial trials and initial orders for its Felix™ sperm selection system within weeks of launch. This momentum aligns with its global expansion strategy targeting major fertility markets.

AoFrio Limited has successfully closed a renounceable pro-rata rights issue, securing NZ$4.428 million to fund its push into US and European markets and advance AI-driven innovations in cold drink equipment.

IODM Limited has broadened its revenue share agreement with TransferMate, now covering UK and European universities, aiming to deepen its presence in the higher education payments sector.

CleanSpace Holdings has achieved a major regulatory milestone with European EN 12941 certification for its new AGILE loose-fitting PAPR, positioning the company for growth in its largest market and preparing for imminent Australian approval.

Diamond Infraco has officially satisfied multiple regulatory conditions in its takeover offer for Atlas Arteria, freeing the offer from several major hurdles and holding a 34.56% stake.

Boresight Ltd (ASX: BST) is seeking to raise $8 million through a public offer to expand its cost-effective military drone manufacturing, targeting growth in the US and European markets.

Control Bionics advances its neural-signal technology across assistive communication, sports, and medical sectors, securing key US reimbursement and distribution agreements while broadening its international footprint.

Cynata Therapeutics secures a crucial regulatory green light from the EMA’s Paediatric Committee for its CYP-001 treatment in children with acute graft versus host disease, paving the way for sequential adult and paediatric trials in Europe.

4DMedical launches the CLEAR clinical evidence program to accelerate adoption of its CT:VQ™ imaging technology in the US acute pulmonary embolism market, aiming to expand its addressable market to US$3 billion.

4DMedical has leapfrogged into the European lung health market by acquiring Austrian AI imaging firm contextflow, gaining immediate commercial presence and a CE-marked lung cancer screening solution.